PriceTargets.com logo

Sunshine Biopharma - SBFM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 439.57%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.78 As of 12/20/2024 06:45 PM ET
▼ -0.02 (-0.71%)

This chart shows the closing price for SBFM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sunshine Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBFM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBFM

Analyst Price Target is $15.00
▲ +439.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sunshine Biopharma in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 439.57% upside from the last price of $2.78.

This chart shows the closing price for SBFM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Sunshine Biopharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/5/2024AegisReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/7/2023AegisInitiated CoverageBuy$260.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sunshine Biopharma logo
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $2.78
Low: $2.70
High: $2.90

50 Day Range

MA: $2.79
Low: $2.12
High: $3.34

52 Week Range

Now: $2.78
Low: $2.11
High: $608.00

Volume

111,796 shs

Average Volume

268,287 shs

Market Capitalization

$3.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Sunshine Biopharma?

The following Wall Street research analysts have issued stock ratings on Sunshine Biopharma in the last year: Aegis.
View the latest analyst ratings for SBFM.

What is the current price target for Sunshine Biopharma?

0 Wall Street analysts have set twelve-month price targets for Sunshine Biopharma in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 439.6%. Aegis has the highest price target set, predicting SBFM will reach $15.00 in the next twelve months. Aegis has the lowest price target set, forecasting a price of $15.00 for Sunshine Biopharma in the next year.
View the latest price targets for SBFM.

What is the current consensus analyst rating for Sunshine Biopharma?

Sunshine Biopharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SBFM will outperform the market and that investors should add to their positions of Sunshine Biopharma.
View the latest ratings for SBFM.

What other companies compete with Sunshine Biopharma?

Other companies that are similar to Sunshine Biopharma include Marinus Pharmaceuticals, PharmaCyte Biotech, Sol-Gel Technologies, ANEW Medical and Aspira Women's Health. Learn More about companies similar to Sunshine Biopharma.

How do I contact Sunshine Biopharma's investor relations team?

The company's listed phone number is (514) 426-6161 and its investor relations email address is [email protected]. The official website for Sunshine Biopharma is www.sunshinebiopharma.com. Learn More about contacing Sunshine Biopharma investor relations.